Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.

Also called NCT02618824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
National Cardiovascular Center Harapan Kita Hospital Indonesia (from the registry)
Registry
  • NCT NCT02618824
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Indonesia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02618824. Randomized; double masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery
Condition
Congenital Heart Disease
Intervention (Drug)
Histidine Tryptophan Ketoglutarate Solution
Intervention (Other)
Terminal Warm Blood Cardioplegia
Lead sponsor
National Cardiovascular Center Harapan Kita Hospital Indonesia (class: other)

Record details

Record id
cardio:ct-nct02618824
Content hash
39742f2c6a347f5b7cf3845300749842df508dff0830e139eec6476470992f3c